Education
About Us
Working with TipRanks
Follow Us
BioRestorative Therapies (BRTX)
NASDAQ:BRTX
BRTX Stock Chart & Stats
$1.16
-$0.13(-7.22%)
At close: 4:00 PM EST
$1.16
-$0.13(-7.22%)
Day’s Range― - ―
52-Week Range$0.98 - $2.55
Previous CloseN/A
Volume34.37K
Average Volume (3M)229.75K
Market Cap
$10.30M
Enterprise Value$8.74M
Total Cash (Recent Filing)$4.49M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.08
Next Earnings
Mar 26, 2026EPS Estimate
-0.38Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.33
Shares Outstanding8,876,242
10 Day Avg. Volume28,673
30 Day Avg. Volume229,747
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)1.30
Price to Sales (P/S)27.69
P/FCF Ratio-1.33
Enterprise Value/Market Cap0.85
Enterprise Value/Revenue22.80
Enterprise Value/Gross Profit28.64
Enterprise Value/Ebitda-0.67
Forecast
1Y Price Target
$8.00Price Target Upside589.66% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Market ExpansionBRTX-100 has received IND clearance to move into a Phase 2 study for cervical spinal pain, potentially expanding its market and application.
Product DifferentiationHypoxic culturing makes BRTX-100 differentiated in cell therapy, offering a unique advantage in the market.
Regulatory ApprovalThe company recently received Fast Track designation from FDA, which could expedite the approval process for its treatments.
Bears Say
Clinical Trial EnrollmentBioRestorative has made further progress with enrollment passing the 1/3rd mark.
BioRestorative Therapies News
BRTX FAQ
What was BioRestorative Therapies’s price range in the past 12 months?
BioRestorative Therapies lowest stock price was $0.98 and its highest was $2.55 in the past 12 months.
What is BioRestorative Therapies’s market cap?
BioRestorative Therapies’s market cap is $10.30M.
When is BioRestorative Therapies’s upcoming earnings report date?
BioRestorative Therapies’s upcoming earnings report date is Mar 26, 2026 which is in 92 days.
How were BioRestorative Therapies’s earnings last quarter?
BioRestorative Therapies released its earnings results on Nov 12, 2025. The company reported -$0.33 earnings per share for the quarter, beating the consensus estimate of -$0.36 by $0.03.
Is BioRestorative Therapies overvalued?
According to Wall Street analysts BioRestorative Therapies’s price is currently Undervalued.
Does BioRestorative Therapies pay dividends?
BioRestorative Therapies does not currently pay dividends.
What is BioRestorative Therapies’s EPS estimate?
BioRestorative Therapies’s EPS estimate is -0.38.
How many shares outstanding does BioRestorative Therapies have?
BioRestorative Therapies has 8,876,242 shares outstanding.
What happened to BioRestorative Therapies’s price movement after its last earnings report?
BioRestorative Therapies reported an EPS of -$0.33 in its last earnings report, beating expectations of -$0.36. Following the earnings report the stock price went down -9.42%.
Which hedge fund is a major shareholder of BioRestorative Therapies?
Currently, no hedge funds are holding shares in BRTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
BioRestorative Therapies
BioRestorative Therapies, Inc., a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders. Its disc/spine program (brtxDisc) includes a lead cell therapy candidate, BRTX-100, a product candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, which has completed Phase 1 clinical trials for use in the non-surgical treatment of painful lumbosacral disc disorders. The company is also developing Metabolic Program (ThermoStem), a cell-based therapy candidate that is in preclinical stage to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. In addition, it provides investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; a research agreement with Pfizer, Inc.; and a research collaboration agreement with the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. BioRestorative Therapies, Inc. was incorporated in 1997 and is based in Melville, New York.
BRTX Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted significant milestones in the company's clinical and commercial development, such as the Fast Track designation for BRTX-100 and a new patent for ThermoStem. However, these were counterbalanced by a sharp revenue decline and increased net loss compared to the previous year. Despite the financial setbacks, the overall sentiment is cautiously optimistic with strategic developments and a strengthened financial position.View all BRTX earnings summariesBRTX Stock 12 Month Forecast
Average Price Target
$8.00
▲(589.66% Upside)
Technical Analysis
Cellectar Biosciences
―
Marker Therapeutics
―
Cocrystal Pharma
―
Sensei Biotherapeutics
―
AEON Biopharma
―
Ownership Overview
4.27% Insiders
1.15% Mutual Funds
1.15% Other Institutional Investors
92.88% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---